{"nctId":"NCT05099640","briefTitle":"A Study of PTC923 in Participants With Phenylketonuria","startDateStruct":{"date":"2021-09-30","type":"ACTUAL"},"conditions":["Phenylketonuria"],"count":157,"armGroups":[{"label":"Part 1: PTC923","type":"EXPERIMENTAL","interventionNames":["Drug: PTC923"]},{"label":"Part 2: PTC923","type":"EXPERIMENTAL","interventionNames":["Drug: PTC923"]},{"label":"Part 2: Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"PTC923","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Uncontrolled blood Phe level ≥360 μmol/L on current therapy anytime during screening and uncontrolled blood Phe level ≥360 μmol/L on current therapy when taking the average of the 3 most recent Phe levels from the participant's medical history (inclusive of the screening value).\n* Clinical diagnosis of phenylketonuria with hyperphenylalaninemia (HPA) documented by past medical history of at least 2 blood Phe measurements ≥600 μmol/L.\n* Women of childbearing potential must have a negative pregnancy test at screening and agree to abstinence or the use of at least one highly effective form of contraception for the duration of the study, and for up to 90 days after the last dose of study drug.\n* Males who are sexually active with women of childbearing potential who have not had a vasectomy must agree to use a barrier method of birth control during the study and for up to 90 days after the last dose of study drug. Males must also refrain from sperm donations during this time period.\n* Willing to continue current diet unchanged while participating in the study.\n\nExclusion Criteria:\n\n* Gastrointestinal disease (such as irritable bowel syndrome, inflammatory bowel disease, chronic gastritis, and peptic ulcer disease, etc.) that could affect the absorption of study drug.\n* History of gastric surgery, including Roux-en-Y gastric bypass surgery or an antrectomy with vagotomy, or gastrectomy.\n* History of allergies or adverse reactions to synthetic tetrahydrobiopterin (BH4) or sepiapterin.\n* Current participation in any other investigational drug study or use of any investigational agent within 30 days prior to screening.\n* Any clinically significant laboratory abnormality as determined by the investigator.\n* A female who is pregnant or breastfeeding, or considering pregnancy.\n* Serious neuropsychiatric illness (for example, major depression) not currently under medical control, that in the opinion of the investigator or sponsor, would interfere with the participant's ability to participate in the study or increase the risk of participation for that participant.\n* Past medical history and/or evidence of renal impairment and/or condition including moderate/severe renal insufficiency (glomerular filtration rate \\[GFR\\] \\<60 milliliters \\[mL\\]/minute \\[min\\]) and/or under care of a nephrologist.\n* Any abnormal physical examination and/or laboratory findings indicative of signs or symptoms of renal disease, including calculated GFR \\<60 mL/min/1.73 square meter (m\\^2).\n* Requirement for concomitant treatment with any drug known to inhibit folate synthesis (for example, methotrexate).\n* Confirmed diagnosis of a primary BH4 deficiency as evidenced by biallelic pathogenic mutations in 6-pyruvoyltetrahydropterin synthase, recessive guanosine-5'-triphosphate (GTP) cyclohydrolase I, sepiapterin reductase, quinoid dihydropteridine reductase, or pterin-4-alpha-carbinolamine dehydratase genes.\n* Major surgery within the prior 90 days of screening.\n* Concomitant treatment with BH4 supplementation (for example, sapropterin dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ).\n* Unwillingness to washout from BH4 supplementation (for example, sapropterin dihydrochloride, KUVAN) or pegvaliase-pqpz (PALYNZIQ)","healthyVolunteers":false,"sex":"ALL","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 2 Double-blind Phase: Mean Change From Baseline in Blood Phenylketonuria (Phe) Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window. Least square (LS) mean and standard error (SE) were calculated using mixed model repeated measures (MMRM) method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-415.75","spread":"24.066"},{"groupId":"OG001","value":"-19.88","spread":"24.223"}]}]}]},{"type":"PRIMARY","title":"Part 2 Double-blind Phase: Percent Change From Baseline in Blood Phe Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window. LS mean and SE were calculated using MMRM method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.40","spread":"3.537"},{"groupId":"OG001","value":"0.82","spread":"3.561"}]}]}]},{"type":"SECONDARY","title":"Part 2 Double-blind Phase: Percentage of Participants With Baseline Phe Levels ≥600 μmol/L Who Achieved Phe Levels <600 μmol/L in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"92.9","spread":null},{"groupId":"OG001","value":"30.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 Double-blind Phase: Percentage of Participants With Baseline Phe Levels ≥360 μmol/L Who Achieved Phe Levels <360 μmol/L in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"84.1","spread":null},{"groupId":"OG001","value":"9.3","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 Double-blind Phase: Mean Change From Baseline in Blood Phe Level at Each 2-Week Period (Averaged Over Each 2-Week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean levels at Weeks 1 and 2, Weeks 3 and 4, and Weeks 5 and 6 were calculated as the average of blood Phe levels collected during the Week 1-2, Week 3-4, and Week 5-6 analysis visit windows, respectively.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-341.18","spread":"226.178"},{"groupId":"OG001","value":"-53.27","spread":"174.461"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-406.88","spread":"199.259"},{"groupId":"OG001","value":"-30.43","spread":"203.425"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-410.07","spread":"204.442"},{"groupId":"OG001","value":"-16.19","spread":"198.642"}]}]}]},{"type":"SECONDARY","title":"Part 2 Double-blind Phase: Percent Change From Baseline in Blood Phe Level at Each 2-Week Period (Averaged Over Each 2-Week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean levels at Weeks 1 and 2, Weeks 3 and 4, and Weeks 5 and 6 were calculated as the average of blood Phe levels collected during the Week 1-2, Week 3-4, and Week 5-6 analysis visit windows, respectively.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.55","spread":"4.265"},{"groupId":"OG001","value":"-6.04","spread":"4.285"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-62.46","spread":"3.220"},{"groupId":"OG001","value":"-1.43","spread":"3.257"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-63.40","spread":"3.537"},{"groupId":"OG001","value":"0.82","spread":"3.561"}]}]}]},{"type":"SECONDARY","title":"Part 1 Open-label Run-in Phase: Plasma Concentration of Tetrahydrobiopterin (BH4) and Sepiapterin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.6","spread":"5.34"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.3","spread":"13.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"107","spread":"76.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"236","spread":"124"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"289","spread":"170"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"245","spread":"131"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"205","spread":"130"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.5","spread":"21.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"94.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"105","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.939","spread":"0.940"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.22","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.06","spread":"1.10"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","spread":"1.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.60","spread":"2.13"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.493","spread":"0.598"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.436","spread":"0.987"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.33","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.82","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2 Double-blind Phase: Plasma Concentration of BH4 and Sepiapterin","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6.63","spread":"3.60"},{"groupId":"OG001","value":"8.52","spread":"4.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"351","spread":"184"},{"groupId":"OG001","value":"12.4","spread":"1.74"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.04","spread":"3.13"},{"groupId":"OG001","value":"4.27","spread":"4.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"401","spread":"184"},{"groupId":"OG001","value":"11.3","spread":"8.70"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.8","spread":"6.29"},{"groupId":"OG001","value":"9.70","spread":"4.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"406","spread":"57.5"},{"groupId":"OG001","value":"12.2","spread":"4.46"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.0","spread":"6.43"},{"groupId":"OG001","value":"9.41","spread":"4.58"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"442","spread":"197"},{"groupId":"OG001","value":"11.4","spread":"3.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.000"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.620","spread":"1.07"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.000"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.23","spread":"1.26"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.000"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.17","spread":"1.09"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.000","spread":"0.000"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":"1.14"},{"groupId":"OG001","value":"0.000","spread":"0.000"}]}]}]},{"type":"SECONDARY","title":"Part 1 Open-label Run-in Phase: Area Under the Concentration-time Curve From Time 0 to 24 Hours Postdose (AUC0-24h) of Sepiapterin and BH4 Following the First Dose of Sepiapterin at 60 mg/kg","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2990","spread":"1450"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":"20.1"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","description":"An adverse event (AE) was as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. TEAEs were considered:\n\n* Part 1 TEAEs, which included all AEs occurring after first dose in Part 1 but before first dose in Part 2;\n* Part 2 TEAEs, which included all AEs after first randomized dose in Part 2. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"68","spread":null},{"groupId":"OG001","value":"33","spread":null},{"groupId":"OG002","value":"18","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 2 Double-blind Phase: Mean Change From Baseline in Blood Phe Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Classical PKU Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Classical PKU participants: Participants with severe forms of PKU, typically very high blood Phe levels (\\>1200 μmol/L). Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window. LS mean and SE were calculated using MMRM method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-488.19","spread":"50.532"},{"groupId":"OG001","value":"4.03","spread":"46.496"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 2 Double-blind Phase: Percent Change From Baseline in Blood Phe Level to Weeks 5 and 6 (Averaged Over a 2-week Period) in Classical PKU Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Classical PKU participants: Participants with severe forms of PKU, typically very high blood Phe levels (\\>1200 μmol/L). Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 2, and mean level at Weeks 5 and 6 was calculated as the average of blood Phe levels collected during the Week 5-6 analysis visit window. LS mean and SE were calculated using MMRM method.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-55.83","spread":"9.182"},{"groupId":"OG001","value":"18.90","spread":"8.286"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 Open-label Run-in Phase: Mean Change From Baseline (Part 1) in Blood Phe Level to Weeks 1 and 2 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 1 Open-label Run-in Phase, and mean level at Weeks 1 and 2 was calculated as the average of blood Phe levels collected during the Week 1-2 analysis visit window. LS mean and SE were calculated using MMRM method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-462.17","spread":"203.620"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Part 1 Open-label Run-in Phase: Percent Change From Baseline (Part 1) in Blood Phe Level to Weeks 1 and 2 (Averaged Over a 2-week Period) in Participants With Phe Reduction From Baseline ≥30% During Part 1","description":"Baseline was defined as the average of Day -1 and Day 1 predose blood Phe levels in Part 1 Open-label Run-in Phase, and mean level at Weeks 1 and 2 was calculated as the average of blood Phe levels collected during the Week 1-2 analysis visit window. LS mean and SE were calculated using MMRM method.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-65.25","spread":"15.764"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":157},"commonTop":["Diarrhoea","Upper respiratory tract infection","Gastroenteritis","Headache","Nasopharyngitis"]}}}